Dangane da sakamakon binciken gwaji na asibiti na musamman na duniya, wasu marasa lafiya da ke fama da ciwon daji na hanji na III waɗanda ke yin aikin tiyatar ciwace-ciwacen ciwace-ciwacen su da ƙwayoyin lymph na iya ƙila ba su buƙatar daidaitaccen chemotherapy na wata shida bayan chemotherapy. Sabanin haka, ga yawancin marasa lafiya marasa lafiya, watanni uku na chemotherapy ba ya ƙara yawan adadin ciwon daji kuma zai iya hana illa masu cutarwa, ciki har da lalacewar jijiyar da maganin oxaliplatin na chemotherapy ya haifar, ko ciwo na dindindin, ƙwaƙwalwa da tingling.
This is a global trial launched in 2007 on the International Duration Assessment of Adjuvant Chemotherapy (IDEA). Six parallel Phase III trials in 12 countries in North America, Europe and Asia enrolled 12,834 eligible patients. Patients with stage III ciwon daji usually use FOLFOX or CAPOX chemotherapy for standard treatment after surgery. The researchers randomly assigned patients to treatment groups of three or six months.
Results: Three months of chemotherapy is not suitable for all patients. Instead, the data shows that the duration of chemotherapy should be determined based on the combination of drugs used and the individual characteristics of the patient ’s cancer: the degree of tumo deposition on the colon wall and the number of lymph nodes that the cancer has spread to. For low-risk patients-those with shallow tumors and affected lymph nodes-treatment with CAPOX for 3 months has been shown to be safe and effective, with little side effects, the same as the progression-free survival (PFS) of six months of treatment. However, in some cases, a six-month course of treatment is better for high-risk patients.
Dokta Anthony Shields, malami a Makarantar Koyon Magunguna ta Jami'ar Jihar Wayne, ya ce a aikace, na yi amfani da wadannan sabbin ka'idoji ga marasa lafiya masu fama da cutar sankara mai saurin kamuwa da cutar hanji, wanda ke kiyaye musu lokaci mai yawa na jiyya kuma yana iya hana cutar watanni shida na tasirin cutar sankara. Kimanin marasa lafiya 400,000 a duk duniya suna ɗaukar mahimmancin magani na oxaliplatin a matsayin tsarin kula da cutar shan magani bayan aiki, don haka waɗannan binciken zasu sami babban tasiri.
